Grace Therapeutics Inc (GRCE)

$3.66 +0.30 (8.93%)
Market Cap 34.07M
Revenue (ttm) 0.00
Net Income (ttm) -12.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 31,800
Avg Vol 66,150
Day's Range N/A - N/A
Shares Out 10.14M
Stochastic %K 26%
Beta 1.43
Analysts Strong Sell
Price Target $10.14

Latest News on GRCE

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Jan 7, 2025, 8:00 AM EST - 10 days ago

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Oct 25, 2024, 8:00 AM EDT - 3 months ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Sep 25, 2024, 7:30 AM EDT - 4 months ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 10:35 AM EDT - 4 months ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Aug 9, 2024, 8:00 AM EDT - 5 months ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Jun 27, 2024, 4:05 PM EDT - 7 months ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Jun 21, 2024, 8:00 AM EDT - 7 months ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Acasti Pharma to Attend BIO International Convention 2024

May 28, 2024, 4:05 PM EDT - 8 months ago

Acasti Pharma to Attend BIO International Convention 2024

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 12, 2024, 8:00 AM EST - 1 year ago

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Feb 1, 2024, 8:00 AM EST - 1 year ago

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Dec 13, 2023, 8:00 AM EST - 1 year ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Nov 13, 2023, 8:00 AM EST - 1 year ago

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Oct 4, 2023, 8:00 AM EDT - 1 year ago

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Acasti Announces $7.5 Million Private Placement Equity Financing

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Acasti Announces $7.5 Million Private Placement Equity Financing

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 11, 2023, 7:00 AM EDT - 1 year ago

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Aug 9, 2023, 4:05 PM EDT - 1 year ago

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 10, 2023, 9:00 AM EDT - 1 year ago

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 7, 2023, 8:00 AM EDT - 1 year ago

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Jul 5, 2023, 9:00 AM EDT - 1 year ago

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Jun 23, 2023, 7:00 AM EDT - 1 year ago

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Acasti Announces Appointment of New Scientific Advisory Board Members

Jun 22, 2023, 9:00 AM EDT - 1 year ago

Acasti Announces Appointment of New Scientific Advisory Board Members

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 17, 2023, 9:00 AM EDT - 1 year ago

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

May 8, 2023, 7:00 AM EDT - 1 year ago

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Apr 4, 2023, 8:01 AM EDT - 1 year ago

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Acasti Announces Appointment of Prashant Kohli as CEO

Apr 4, 2023, 8:00 AM EDT - 1 year ago

Acasti Announces Appointment of Prashant Kohli as CEO

Acasti Pharma Inc. Announces the Resignation of a Director

Mar 30, 2023, 8:30 AM EDT - 1 year ago

Acasti Pharma Inc. Announces the Resignation of a Director

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Mar 13, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Mar 8, 2023, 9:00 AM EST - 2 years ago

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Acasti Pharma Recognizes Rare Disease Day

Feb 28, 2023, 1:00 PM EST - 2 years ago

Acasti Pharma Recognizes Rare Disease Day

Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript

Feb 14, 2023, 3:53 PM EST - 2 years ago

Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript

Acasti Pharma Reports Third Quarter 2023 Operational Results

Feb 14, 2023, 7:00 AM EST - 2 years ago

Acasti Pharma Reports Third Quarter 2023 Operational Results

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

Feb 7, 2023, 9:00 AM EST - 2 years ago

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Jan 25, 2023, 9:00 AM EST - 2 years ago

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

Jan 24, 2023, 4:15 PM EST - 2 years ago

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

Jan 17, 2023, 8:45 AM EST - 2 years ago

Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

Jan 13, 2023, 9:00 AM EST - 2 years ago

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

Jan 5, 2023, 9:00 AM EST - 2 years ago

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

Dec 28, 2022, 8:00 AM EST - 2 years ago

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript

Nov 14, 2022, 11:23 PM EST - 2 years ago

Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript

Acasti Pharma Reports Second Quarter 2023 Operational Results

Nov 14, 2022, 7:00 AM EST - 2 years ago

Acasti Pharma Reports Second Quarter 2023 Operational Results

Acasti Pharma to Present at Q4 Investor Summit

Nov 9, 2022, 4:15 PM EST - 2 years ago

Acasti Pharma to Present at Q4 Investor Summit

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

Nov 7, 2022, 4:15 PM EST - 2 years ago

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

Acasti Announces Court Dismissal of Stockholder Litigation

Sep 30, 2022, 9:00 AM EDT - 2 years ago

Acasti Announces Court Dismissal of Stockholder Litigation

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

Sep 29, 2022, 9:00 AM EDT - 2 years ago

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast

Sep 21, 2022, 8:45 AM EDT - 2 years ago

Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

Sep 14, 2022, 4:15 PM EDT - 2 years ago

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

Sep 13, 2022, 8:00 AM EDT - 2 years ago

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 12, 2022, 9:00 AM EDT - 2 years ago

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference